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Objective: Thromboembolic events in patients who have undergone the Fontan
operation have been reported to be as high as 20% to 33%. A hypercoagulable state
with deficiencies in proteins C and S has been implicated. Using age-matched con-
trol subjects, we evaluated whether an altered coagulation state is present earlier in
the course of staged single-ventricle repair.
Methods: After informed consent had been obtained, coagulation factors were
assayed in 36 infants (mean age, 7.7 ± 3.6 months) with single-ventricle cardiac
defects immediately before undergoing the bidirectional Glenn procedure; 34
infants (mean age, 8.4 ± 2.6 months) without cardiac disease were assayed as con-
trol subjects. Concentration of factors II, V, VII, VIII, IX, and X; antithrombin III;
plasminogen; proteins C and S; fibrinogen; serum albumin; and liver enzymes were
measured. Normal reference intervals on the basis of the control subjects were
determined by using 95% confidence limits. Patient demographic and hemody-
namic variables were evaluated as possible predictors of coagulation abnormalities.
Results: Concentrations of protein C; factors II, V, VII, IX, and X; plasminogen; fib-
rinogen; and antithrombin III were significantly lower in the pre-Glenn infants com-
pared with in the age-matched control subjects (all P < .001, Student t test). On the
basis of multiple logistic regression, no specific hemodynamic variables were pre-
dictive of a procoagulant or anticoagulant deficiency. Ventricular dysfunction did
predict the presence of multiple coagulation abnormalities (P < .001).
Conclusion: Procoagulant and anticoagulant factor abnormalities occur early in the
course of single-ventricle repair and precede the cavopulmonary connection.
The Fontan operation is currently performed for children older than 1year with a wide variety of congenital heart defects that preclude a 2-ventricle repair. It separates the systemic and pulmonary circulationssuch that the systemic venous return is directed to the lungs in theabsence of a pulmonary ventricle. Since the original Fontan opera-tion,1 several modifications have been undertaken that have improved
early and late mortality and morbidity. For example, a recent study by Stamm and
colleagues2 reported long-term follow-up of 220 patients who had undergone the lat-
eral tunnel modification of the Fontan operation for various cardiac malformations.
An estimated survival of 93% at 5 years and 91% at 10 years was reported.
Nevertheless, these patients continue to have numerous abnormalities that compli-
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cate perioperative management and compromise long-term
outcome.3 Thromboembolic events, arrhythmias, and pro-
tein-losing enteropathy are particularly problematic.4
Thromboembolism may occur in the immediate postoper-
ative period or later. The incidence of thromboembolic events
in patients with Fontan physiology is uncertain but may be as
high as 20% to 33% overall.5-7 Increased venous pressure,
hepatic dysfunction, stasis of flow through the right atrial
baffle and pulmonary circulation, and increased resting
venous tone are some of the factors that may contribute to an
increased risk of clot formation in patients with Fontan phys-
iology. Furthermore, abnormal coagulation parameters after
the Fontan procedure involving both procoagulant and anti-
coagulant factors have also been described.8-11
These previous studies suggested that the alterations in
the coagulation factors found in some patients undergoing
the Fontan procedure are a direct consequence of the
anatomic and physiologic changes that result from the
Fontan operation. However, it is possible that coagulation
abnormalities may occur earlier in patients with single-ven-
tricle disease, either because of other physiologic derange-
ments (eg, cyanosis, low cardiac output, and venous
congestion) or perhaps because of genetic predisposition.
Coagulation status has not been assessed earlier in the
course of patients with single-ventricle physiology. A major
limitation of the previous studies that strongly implicated
Fontan physiology as the primary cause of abnormal clot-
ting parameters is the lack of age-appropriate control sub-
jects.12,13 Establishing age-related normal values in infants
and children is critical to correctly addressing this question
because coagulation factor concentrations and activities
mature significantly and at varying rates after birth, with
some not approaching adult values until late childhood.12-15
We therefore conducted this single-center prospective
cohort study to delineate coagulation parameters in infants
with single-ventricle physiology before the bidirectional
Glenn (BDG) and Fontan procedures. This was done by
evaluating procoagulant and anticoagulant factor levels
immediately before the BDG procedure and using normal
infants of similar age without congenital heart disease as
age-matched control subjects.
Methods
After institutional review board approval and informed parental
consent had been obtained, 36 patients between the ages of 3.2 and
19 months with a variety of single-ventricle congenital heart
defects were prospectively enrolled immediately before undergo-
ing a BDG procedure. Patients were excluded if they had preexist-
ing hematologic disorders or concurrent coagulopathies or if the
patients were receiving warfarin sodium (Coumadin); 23 patients
had been receiving aspirin, but this was discontinued 7 to 10 days
before the operation.
Blood samples from all patients (8 mL) were obtained from a
central venous catheter or an indwelling arterial catheter at 2 time
points: (1) immediately after induction of general anesthesia and
(2) 24 hours postoperatively in the intensive care unit (ICU).
Measured parameters included hemoglobin level, hematocrit level,
platelet count, prothrombin time (PT), and activated partial pro-
thrombin time (APTT). The circulating anticoagulant factors mea-
sured were protein C, protein S, plasminogen, and antithrombin
III; the procoagulant factors measured were factors II, V, VII, VIII,
IX, and X and fibrinogen.
The Coulter T 660 (Beckman Coulter, Inc, Miami, Fla) auto-
mated hematology analyzer was used to measure hemoglobin,
hematocrit, and platelet levels. Coefficients of variation within and
between assays at levels 1, 2, and 3 were as follows: hemoglobin,
1.8%, 1.0%, and 0.9%; hematocrit, 1.8%, 1.2%, and 1.5%; and
platelets, 4.8%, 2.7%, and 1.8%, respectively.
The ACL 3000 Plus (Automated Coagulation Laboratory,
Beckman Coulter, Inc, Fullerton, Calif) was used to assay the indi-
vidual procoagulant and anticoagulant factors, as well as the PT
and APTT. The ACL device contains 2 measuring systems: (1)
nephelometry, which is used to detect clot formation as the end
point, and (2) photometry, which is used for reading chromogenic
substrate assays. Blood for these assays was collected in citrated
plasma (3.2% buffered sodium citrate) from an indwelling can-
nula, from which 10 mL of blood had been aspirated to remove
residual heparin. The blood was immediately centrifuged at
13,000 rpm for 5 minutes, and the plasma layer was removed. The
PT, APTT, and fibrinogen levels were measured immediately by
means of nephelometry (coefficient of variation, respectively: PT,
1.2% and 2.3%; APTT, 2.1% and 4.8%; and fibrinogen, 3.1% and
5.5%). Remaining plasma was stored at –70°C in 200-µL aliquots
for batch performance of the other coagulation assays, as
described below.
Protein C and S activity were both measured by using func-
tional clotting assays. Protein C activity was determined on the
basis of the prolongation of the APTT by using the Staclot Protein
C kit (Diagnostica Stago, Asnieres-Sur-Seine, France), according
to the manufacturer’s directions. In this assay, activated protein C
inhibits factor V and VIII activity, thus prolonging the APTT of a
system in which all the factors, with the exception of protein C, are
present in excess; protein C is derived from the sample being
tested (coefficient of variation, 1.8% and 2.4%).
Protein S activity was determined on the basis of the principle
of factor Va inhibition by using the Staclot Protein S kit
(Diagnostica Stago). The principle of the test is based on the
cofactor activity of protein S, which enhances the anticoagulant
action of activated protein C. This enhancement is reflected by the
prolongation of the clotting time of a system enriched with factor
Va (coefficient of variation, 7.9% and 3.8%).
Extrinsic coagulation factors (factors II, V, VII, and X) were
each determined by performing a modified PT assay. Intrinsic
coagulation factors (factors VIII and IX) were determined by
performing a modified APTT assay. In these assays correction of
the clotting time of plasma specifically deficient in the factor
being tested is proportional to the concentration (activity per-
centage) of that factor in the patient plasma interpolated from a
calibration curve. Factor-deficient plasma factors II, V, VII, VIII,
IX, and X were obtained from Instrument Laboratory
(Lexington, Mass; coefficients of variation, respectively: factor
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II, 2.3% and 2.7%; factor V, 3.3% and 2.3%; factor VII, 2.5% and
2.2%; factor VIII, 4.9% and 3.7%; factor IX, 3.2% and 3.1%; and
factor X, 3.0% and 2.0%).
Antithrombin III activity was determined by using a synthetic
chromogenic substrate assay based on factor Xa inactivation
(antithrombin III, Instrument Laboratory; coefficient of variation,
4.3% and 2.8%). Plasma plasminogen was activated through reac-
tion with an excess of streptokinase in the presence of fibrinogen.
Plasminogen content was then determined on the basis of a syn-
thetic chromogenic substrate assay, according to the manufac-
turer’s directions (Plasminogen, Instrument Laboratory;
coefficient of variation, 4.5% and 3.7%).
Because altered hepatic dysfunction can contribute to coagula-
tion factor abnormalities, serum alkaline phosphatase, gamma-
glutamyl transferase, alanine transaminase, aspartate transaminase,
total bilirubin, albumin, and total protein were measured in all
patients and compared with normal values for our laboratory.
Age-matched Control Coagulation Parameters
After informed written parental consent had been obtained, 34
healthy infants (8 girls and 26 boys; mean age, 8.4 ± 2.6 months;
age range, 3-13 months) undergoing minor day surgical proce-
dures were studied. A total of 1.8 mL of blood was taken from
each patient after placement of an intravenous catheter and col-
lected into citrated plasma (3.2% buffered sodium citrate). Blood
samples were immediately centrifuged at 13,000 rpm for 5 min-
utes, and the plasma was stored at –70°C for subsequent batch
analyses. Proteins C and S, plasminogen, fibrinogen, antithrombin
III, and factors II, V, VII, VIII, IX, and X were analyzed as
described above.
Potential Hemodynamic Factors
As part of the routine preoperative evaluation, all patients under-
went elective cardiac catheterization and echocardiography.
Ventricular morphology (morphologic right or left systemic ven-
tricle), ventricular function, and atrioventricular valve and semilu-
nar valve function were assessed by means of preoperative
echocardiography. Superior vena cava oxygen saturation (SvO2),
the ratio of pulmonary to systemic blood flow (Qp/Qs), atrial pres-
sure, pulmonary artery pressure, systemic ventricular end-diastolic
pressure (EDP), and the presence of systemic ventricle outflow
obstruction or aortic arch obstruction were assessed by means of
preoperative cardiac catheterization.
Statistical Analysis
An a priori power analysis revealed that a total sample of 60
patients (30 control and 30 BDG patients) would provide 82%
power to detect an effect size of 1.0 (mean difference/common
SD) with respect to each of the 11 coagulation factors and protein
levels on the basis of a 2-sample Student t test applying a
Bonferroni-corrected α level of .005 (ie, 0.05/11). This sample
size would also provide a statistical power exceeding 95% for
comparisons between pre- and post-BDG values on the basis of
paired t tests (version 4.0, nQuery Advisor; Statistical Solutions,
Boston, Mass). All 11 coagulation and protein variables were
assessed for normality by the Wilk-Shapiro test, and no significant
departures were identified. Normal reference ranges were based
on the empirical 95% confidence intervals and defined according
to 2.5 and 97.5 percentiles.16 Control values were compared with
pre- and post-BDG values by using the 2-sample Student t test.
Changes between pre- and post-BDG values were evaluated with
paired t tests. Univariate and multiple stepwise logistic regression
was used to determine whether any patient, hemodynamic, or lab-
oratory variables were predictive of a coagulation abnormality.
Candidate variables considered in these analyses included sex,
weight, prior procedure, ventricle morphology (left or right), EDP,
SvO2, Qp/Qs ratio, common atrial pressure, ventricular function,
atrioventricular valve regurgitation, and serum albumin levels. The
likelihood ratio test was used to determine the significance of pre-
dictors. In addition, multiple linear regression was used to deter-
mine any predictors of the number of coagulation abnormalities,
ranging from 0 to 11. For comparisons between control patients
and pre-BDG and post-BDG patients, a Bonferroni corrected P <
.005 was considered significant to account for the 11 coagulation
variables being compared. Analysis of the data was performed
with the SPSS (version 10.1; SPSS Inc, Chicago, Ill) and SAS
(version 6.12; SAS Institute, Cary, NC) software packages.
Continuous variables are expressed in terms of means ± SD. All
reported P values are 2-tailed.
Results
The mean age for the 36 patients (15 girls and 21 boys) was
7.7 ± 3.6 months, and the mean weight was 6.3 ± 1.2 kg.
Patient diagnoses and prior procedures are summarized in
Table 1; 21 patients had a morphologically right ventricle,
and 15 had a morphologically left ventricle. Prior proce-
dures in the patients are also included in Table 1. Pre-BDG
hemodynamic variables, as assessed either with echocar-
diography or cardiac catheterization, are shown in Table 2.
TABLE 1. Cardiac diagnoses of patients undergoing BDG
Diagnosis No. Prior operation
DORV 7 1 Norwood, 5 BTS, 1 PAB
DORV/PS 2 None
DORV/PA 1 BTS
DORV/malalignment CAVC 1 None
HLHS 8 8 Norwood
PA/TGA 2 2 BTS
TA/NRGV 5 2 BTS/2 Norwood
TA/TGA 1 PAB
TA/PS 2 1 BTS/1 Norwood
TA/PA 1 BTS
DILV 2 1 BTS/1 Norwood
DILV/PS 2 1 PPM/1 None
TGA/PS 1 None
TGA/IAA 1 Norwood
DORV, Double-outlet right ventricle; PS, pulmonary stenosis; PA, pul-
monary atresia; CAVC, common atrioventricular canal defect; HLHS,
hypoplastic left heart syndrome; TGA, transposition of great arteries; TA,
tricuspid atresia; NRGV, normal related great vessels; DILV, double-inlet
left ventricle; IAA, interrupted aortic arch; BTS, Blalock-Taussig shunt;
PAB, pulmonary artery band; PPM, permanent pacemaker.
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For control subjects, the mean age was 8.4 ± 2.6 months.
The calculated normal reference ranges for coagulation fac-
tors are shown in Table 3. Normal ranges were based on the
empirical 95% confidence intervals derived from the 2.5
and 97.5 percentile confidence limits.
The mean hematocrit, platelet count, PT, APTT, and liver
function test results for patients before the BDG procedure
are shown in Table 4. In all but one patient, abnormal PT,
PTT, or both values corrected when calibration plasma
(Instrumentation Laboratories) was added in a 50:50 ratio to
patient plasma. Calibration plasma is obtained from healthy
donors and is processed to maintain the characteristics of
normal plasma. Normalization by calibration plasma indi-
cates one or more factor deficiencies as the cause of the PT
or PTT prolongation (as opposed to circulating anticoagu-
lants such as heparin). In one patient these values did not
normalize, which was interpreted as heparin contamination;
this patient was excluded for evaluation of PT and PTT.
There were no correlations between the liver-function
abnormalities and factor abnormalities.
The comparison between coagulation factors in infants
before the BDG procedure and healthy control subjects is
summarized in Table 5. Significant reductions in both pro-
coagulant and anticoagulant factor levels were detected
before the BDG in all 36 patients. The most common abnor-
malities were low levels of factor II (25/36), factor V
(26/36), factor X (25/36), and protein C (23/36).
Univariate and multivariate logistic regression were used
to examine the relationship of the 11 variables (ie, sex,
weight, prior procedure, ventricle morphology [left or right],
EDP, SvO2, Qp/Qs ratio, common atrial pressure, ventricu-
lar function, atrioventricular valve regurgitation, and serum
albumin level) to specific coagulation factor abnormalities.
For individual variables, a low serum albumin level was pre-
dictive of an abnormality in factor II, decreased ventricular
function by echocardiography was predictive of an abnor-
mality in factor VII, and a low SvO2 was predictive of an
abnormality in factor X (all P < .001). The only significant
predictor for multiple coagulation factor abnormalities was
decreased ventricular function (P < .001).
According to institutional practice, the cardiopulmonary
bypass (CPB) circuit for all patients was primed with whole
blood (WB) to achieve a hematocrit level of approximately
30%. Patients received 2 mg/kg heparin before aortic cannu-
lation and an additional 2 mg/kg in the circuit prime. The
initial activated clotting time on CPB was greater than 500
seconds in all patients, despite the low antithrombin III level
subsequently noted in 33% of the patients. Fifteen patients
were transfused in the operating room with WB (mean vol-
ume, 163 ± 93 mL), 18 with packed red blood cells (mean
volume, 144 ± 100 mL), 25 with platelets (mean volume, 69
± 22 mL), and 14 with cryoprecipitate (mean volume, 32 ±
14 mL); no patient received fresh frozen plasma, and 2
patients did not receive any blood products in the operating
room but were transfused in the ICU postoperatively. An
antifibrinolytic was administered intraoperatively to 16
TABLE 2. Preoperative hemodynamic characteristics
No. (%)
Ventricular function
Normal 25 (71%)
Mildly depressed 8 (23%)
Moderately-severely depressed 2 (6%)
AVVR
No regurgitation 12 (34%)
Trivial-mild 21 (60%)
Moderate-severe 2 (6%)
EDP
Mean (mm Hg) 9.1 ± 3.9
<12 mm Hg 22 (69%)
≥12 mm Hg 10 (31%)
Atrial pressure
Mean (mm Hg) 6.6 ± 4.2
<5 mm Hg 12 (36%)
≥5 mm Hg 21 (64%)
PAP
Mean (mm Hg) 16 ± 5.4
<12 mm Hg 5 (16%)
≥12 mm Hg 27 (84%)
Qp/Qs 1.5 ± 0.9
PaO2 (mm Hg) 47 ± 10
SvO2 (%) 50 ± 10
SpO2 (%) 80 ± 10
Data are expressed as number (%) or mean ± SD as shown. AVVR,
Atrioventricular valve regurgitation; PAP, pulmonary artery pressure;
SpO2 , oxygen saturation.
TABLE 3. Normal ranges for coagulation factors and serum
protein levels, as established from control subjects
Variable Median Mean Normal range*
Fibrinogen (mg/L) 268 278 178-555
Factor II 89 90 69-122
Factor V 115 117 84-152
Factor VII 86 89 36-142
Factor VIII 77 77 40-130
Factor IX 66 66 41-104
Factor X 92 94 72-134
Antithrombin III 108 106 67-132
Plasminogen 90 89 60-120
Protein C 84 84 50-134
Protein S 83 88 45-135
All factors except fibrinogen are expressed as percentage of activity.
*Normal ranges were based on empirical 95% confidence intervals
derived from the 2.5 and 97.5 percentile limits (n = 34, except fibrinogen: n
= 16).
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patients (15 received traneximic acid and 1 received apro-
tinin), according to the surgeon’s preference.
The mean chest tube drainage at 24 hours in the ICU was
146 ± 82 mL. Six patients received transfusion with WB
(mean volume, 53 ± 37 mL) within 24 hours in the ICU, 25
patients received packed red blood cells (mean volume, 88
± 29 mL), 2 patients received cryoprecipitate (mean vol-
ume, 35 ± 7 mL), 5 patients received platelets (mean vol-
ume, 44 ± 31 mL), and 1 patient received fresh frozen
plasma (30 mL).
Coagulation factors were assayed in the ICU 24 hours
postoperatively. All factor levels were below the normal
range when compared with those of our age-matched con-
trol subjects, except factor VIII and fibrinogen, which were
significantly higher. When pre- and post-BDG levels were
compared within the same patients, fibrinogen and factor
VIII and IX values were significantly higher than preopera-
tive values (all P < .001), and in addition, factor VII and
protein S values were significantly lower than preoperative
values (P < .001 for each).
One patient with hypoplastic left heart syndrome who
had previously undergone a Norwood procedure had a large
clot in the common atrium on postoperative day 2, with sub-
sequent low cardiac output requiring extracorporeal mem-
brane oxygenation. Although the patient was taken back to
the operating room for evacuation of the thrombus, she sub-
sequently died on postoperative day 3. All coagulation fac-
tors in this patient before the BDG procedure were in the
low normal range, except for protein C, which was substan-
tially below the norm for age (39%). The immediate post-
BDG factor levels in this patient were also notable for
persistently low protein C level (35%). This patient had not
received an antifibrinolytic agent. All other patients recov-
ered uneventfully without clinical sign of thrombus or prob-
lems with postoperative hemostasis.
Discussion
Our study found that when compared with healthy infants
of similar age, there was a high incidence of both procoag-
ulant and anticoagulant factor abnormalities in patients with
single-ventricle physiology before the cavopulmonary con-
nection. Thus, we conclude that significant abnormalities in
multiple coagulation factors may be present before Fontan
(and BDG) operations.
The finding of coagulation factor abnormalities in chil-
dren with single-ventricle physiology has been previously
reported after the Fontan operation. Cromme-Dijkhuis and
colleagues9 examined 37 patients for coagulation factor
abnormalities to determine whether prothrombotic risk fac-
tors could explain the increased incidence of thromboem-
bolism observed after the Fontan procedure. The most
pronounced abnormality was a deficiency of protein C;
additionally, the concentrations of antithrombin III and fac-
tors II and X were significantly lower in protein C–deficient
patients than in those with normal protein C concentrations.
This study suggested that the high thrombotic risk after the
Fontan operation could be caused by, or at least associated
with, an imbalance between procoagulant and anticoagulant
factors that favored thrombus formation and that one or
more aspects of Fontan physiology were responsible; simi-
lar results and conclusions have been reported by oth-
ers.6,10,11 However, these studies did not examine the full
complement of coagulation factors, did not use age-
matched control subjects, and did not study patients earlier
in their course of single-ventricle physiology.
The hemostatic system matures over the first several
years of life,14,15 leading to important differences in factor
TABLE 5. Mean factor levels between control subjects and
patients immediately before the BDG procedure
No. (%) of pre-BDG
Control Pre-BDG patients below
Variable (n = 34) (n = 36) P value* normal range
Fibrinogen (mg/L) 278 ± 89 187 ± 51 <.001 16 (44)
Factor II (%) 90 ± 12 63 ± 12 <.001 25 (69)
Factor V (%) 117 ± 18 76 ± 18 <.001 26 (72)
Factor VII (%) 89 ± 20 45 ± 12 <.001 7 (19)
Factor VIII (%) 77 ± 19 65 ± 22 .018 3 (8)
Factor IX (%) 66 ± 14 42 ± 9 <.001 17 (47)
Factor X (%) 94 ± 13 69 ± 12 <.001 25 (69)
Antithrombin III (%) 106 ± 12 70 ± 11 <.001 12 (33)
Plasminogen (%) 89 ± 14 70 ± 17 <.001 12 (33)
Protein C (%) 84 ± 18 45 ± 15 <.001 23 (64)
Protein S (%) 88 ± 19 73 ± 20 .002 2 (6)
Data are presented as mean percentage ± SD, except for fibrinogen level
(fibrinogen, n = 18 for control subjects; protein S, n = 31 for pre-BDG
patients).
*Based on 2-sample Student t tests.
TABLE 4. The mean hematocrit, platelet count, coagulation,
and liver function tests before the BDG
No. of patients
outside normal
Pre-BDG range (%) Normal range
Hematocrit (%) 40.9 ± 4.9 1 (3) 33-55
Platelet count (×103) 270 ± 56 0 130-400
PT (s) 13 ± 0.8 15 (42) 11.0-13.0
PTT (s) 56.9 ± 16.5 30 (83) 27-37
Albumin (g/dL) 3.4 ± 0.4 5 (14) 3.0-4.6 
AST (U/L) 33.8 ± 13 6 (16) 2-40 
ALT (U/L) 21.1 ± 11.1 3 (8) 0-35 
GGTP (U/L) 14.7 ± 9.7 0 5-40
ALK (U/L) 277 ± 124 3 (8) 110-400
Bilirubin (mmol/L) 0.8 ± 0.9 5 (14) 0.3-1.2
AST, Aspartate aminotransferase; ALT, alanine aminotransferase; GGTP,
gamma-glutamyl transpepsidase; ALK, alkaline phosphatase.
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and activity measurements in children compared with those
in adults; thus, use of age-matched control subjects is essen-
tial. In general, values of most procoagulant and anticoagu-
lant factors are lowest in neonates and infants and increase
toward adult values at varying rates. One study of 246 chil-
dren aged 1 to 16 years demonstrated that mean values of 7
procoagulants were significantly lower than adult values,
increasing with age. Values for 3 circulating inhibitors also
differed from adult values, with protein C in particular
being significantly lower compared with adult values.14
Despite the observed differences, there is no evidence that
infants are at greater risk for hemorrhagic or thrombotic
problems compared with adults, suggesting that the neona-
tal and infant system is in functional balance at lower con-
centrations of most factors.17
Although many of the coagulation factor levels in our
patients before the BDG procedure were low, postoperative
bleeding did not appear to be a problem. This could indicate
that the coagulation systems in these infants are indeed bal-
anced, which is consistent with the prior observation of
functional maturity of the coagulation system in neonates
and infants.17 However, whether the coagulation factor
abnormalities (compared with those of age-matched control
subjects) we measured in our patients are due to delayed
maturation caused by cyanosis or low cardiac output is
speculative. Severe hepatic synthetic dysfunction (eg,
reduced albumin levels) or evidence of hepatocellular dys-
function (eg, bilirubin or transaminase) did not appear to be
associated with coagulation abnormalities, an important
observation given the prominent role of the liver in the syn-
thesis of procoagulants and anticoagulants and the potential
for altered liver blood flow and oxygen delivery in these
patients. Patients with decreased ventricular function were
more likely to demonstrate multiple factor deficiencies;
however, we were unable to relate specific hemodynamic
variables that could contribute to hepatic congestion or
altered hepatic synthetic function with specific procoagu-
lant or anticoagulant abnormalities. This may in part be due
to the fact that significant hemodynamic abnormalities were
uncommon, which also suggests that the observed factor
abnormalities are unrelated in this group of patients.
Only 5 of our patients had not undergone a surgical pro-
cedure before the BDG operation; nevertheless, there were
no differences in coagulation factor abnormalities in this
small group of patients when compared with patients who
had undergone prior surgery (ie, stage 1 procedure, pul-
monary artery band, or Blalock-Taussig shunt). It is
unknown whether children with congenital heart disease per
se have procoagulant and anticoagulant abnormalities. A
comparison with healthy age-matched control subjects and
measurement of factor levels in nonhypoxic infants with 2-
ventricle physiology congenital heart defects would be nec-
essary to answer this question.
Coagulation factor abnormalities 24 hours after CPB are
difficult to evaluate because of changes in the plasma con-
centration of coagulation proteins from hemodilution during
CPB, consumption coagulopathy, the acute-phase response,
and transfusion of blood products, including cryoprecipitate,
platelets, and WB. In particular, immediate postoperative
increases in the concentrations of fibrinogen and factor VIII,
as reported here, are difficult to interpret because they are
well-described acute-phase reactants.18,19 Whether changes
in these 2 variables represent an acute-phase reaction or
reflect the development of a hypercoagulable state induced
by the BDG procedure, as has been previously concluded for
the Fontan operation,11 cannot be determined. Post-BDG
patients had elevated levels of factor II compared with that
seen in pre-BDG patients. This, combined with low levels of
antithrombin III, could increase the risk for postoperative
thrombosis because the ratio of factor II and antithrombin III
levels has been shown to be more important than protein C
and S levels in terms of thrombotic risk.20 Whether the
potential prothrombotic state described here in the postoper-
ative period persists beyond the immediate postoperative
state in these patients is as yet undetermined.
Previous studies, examining only a limited number of
clotting factors at one point in time and not using age-
matched control subjects, suggested that procoagulant and
anticoagulant factor abnormalities are the result of the
Fontan operation and physiology. They further concluded
that the increased risk of stroke and other thromboembolic
events is the direct outcome of these abnormalities. The
inherent limitations in these conclusions have been empha-
sized recently.12,13 On the basis of the present study, it
appears that multiple procoagulant and anticoagulant factor
abnormalities occur early in the course of single-ventricle
physiology and in fact precede the cavopulmonary connec-
tion. Whether these abnormalities are part of a genetic pre-
disposition or result from other hemodynamic or
pathophysiologic abnormalities and what their contribution
might be to deleterious clinical events require further study.
A prospective, longitudinal evaluation of the changes in
coagulation status in a cohort of patients with the same
diagnosis undergoing staged single-ventricle repair is cur-
rently underway and may help determine the time course of
coagulation abnormalities in these patients.
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